U.S. Jennerex announces positive Phase I clinical results on JX-594

Published: 2007-10-26 06:56:00

Updated: 2007-10-26 06:56:00

The U.S. Jennerex Biotherapeutics said on October 23 that its lead product candidate JX-594, a genetically-engineered vaccinia virus strain, demonstrated objective evidence of efficacy in 10 of the 13 evaluable Korean patients with advanced treatment-refractory tumors in the liver (primary and me...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK